| Immune stimulating properties of a novel polysaccharide from the medicinal plant Tinospora cordifolia PKR Nair, S Rodriguez, R Ramachandran, A Alamo, SJ Melnick, ... International immunopharmacology 4 (13), 1645-1659, 2004 | 249 | 2004 |
| Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines C Ramachandran, S Rodriguez, R Ramachandran, PKR Nair, H Fonseca, ... Anticancer research 25 (5), 3293-3302, 2005 | 210 | 2005 |
| Mechanism of macrophage activation by (1, 4)-α-D-glucan isolated from Tinospora cordifolia PKR Nair, SJ Melnick, R Ramachandran, E Escalon, C Ramachandran International Immunopharmacology 6 (12), 1815-1824, 2006 | 137 | 2006 |
| The updated AMSA scorecard of conflict-of-interest policies: a survey of US medical schools DJ Carlat, T Fagrelius, R Ramachandran, JS Ross, S Bergh BMC medical education 16, 1-8, 2016 | 40 | 2016 |
| Access to COVID-19 vaccines in high-, middle-, and low-income countries hosting clinical trials R Ramachandran, JS Ross, JE Miller JAMA Network open 4 (11), e2134233-e2134233, 2021 | 33 | 2021 |
| Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study MM Dhodapkar, X Shi, R Ramachandran, EM Chen, JD Wallach, JS Ross bmj 379, 2022 | 22 | 2022 |
| Assessment of hypothetical out-of-pocket costs of guideline-recommended medications for the treatment of older adults with multiple chronic conditions, 2009 and 2019 T Zhou, P Liu, SS Dhruva, ND Shah, R Ramachandran, KM Berg, JS Ross JAMA internal medicine 182 (2), 185-195, 2022 | 20 | 2022 |
| Strengthening the FDA’s enforcement of ClinicalTrials. gov reporting requirements R Ramachandran, CJ Morten, JS Ross JAMA 326 (21), 2131-2132, 2021 | 17 | 2021 |
| Immune stimulating properties of a novel polysaccharide from the medicinal plant Tinospora cordifolia PK Raveendran, S Rodrigueza, R Ramachandran, A Alamo, SJ Melnick, ... Int. J. Immunopharmacol 4, 1645-1659, 2004 | 14 | 2004 |
| Comparison of duration of postapproval vs pivotal trials for therapeutic agents granted US Food and Drug Administration accelerated approval, 2009-2018 JD Wallach, R Ramachandran, T Bruckner, JS Ross JAMA Network Open 4 (11), e2133601-e2133601, 2021 | 12 | 2021 |
| US Food and Drug Administration approval of drugs not meeting pivotal trial primary end points, 2018-2021 JL Johnston, JS Ross, R Ramachandran JAMA Internal Medicine 183 (4), 376-380, 2023 | 10 | 2023 |
| Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional study M Mooghali, L Glick, R Ramachandran, JS Ross BMJ open 13 (1), e069115, 2023 | 10 | 2023 |
| Spending by the Centers for Medicare & Medicaid Services before and after confirmation of benefit for drugs granted US Food and Drug Administration accelerated approval, 2012 … JJ Skydel, AC Egilman, JD Wallach, R Ramachandran, R Gupta, JS Ross JAMA Health Forum 3 (5), e221158-e221158, 2022 | 9 | 2022 |
| One health and antimicrobial resistance C Mattar, AS Ore, SK Fagerberg, R Ramachandran, W Tun, E Wiley, ... World Medical Journal 62 (3), 108-111, 2016 | 8 | 2016 |
| Future of covid-19 vaccine pricing: lessons from influenza R Ramachandran, M Dhodapkar, JS Ross, JL Schwartz bmj 373, 2021 | 7 | 2021 |
| Medicare’s National Coverage Determination for Aducanumab—A One-Off or a Pragmatic Path Forward? SS Dhruva, R Ramachandran, JS Ross New England Journal of Medicine 387 (17), 1539-1541, 2022 | 6 | 2022 |
| Commentary: fulfilling the promise of global access licensing principles to enable equitable access R Ramachandran Healthcare Policy 17 (4), 37, 2022 | 6 | 2022 |
| Extending the US Food and Drug Administration’s postmarket authorities HF Lynch, RE Sachs, S Lee, M Herder, JS Ross, R Ramachandran JAMA Health Forum 4 (6), e231313-e231313, 2023 | 5 | 2023 |
| Ensuring public trust in an empowered FDA JS Ross, KM Berg, R Ramachandran New England Journal of Medicine 388 (14), 1249-1251, 2023 | 5 | 2023 |
| Use of expedited regulatory programs and clinical development times for FDA-approved novel therapeutics AK Wong, M Mooghali, R Ramachandran, JS Ross, JD Wallach JAMA Network Open 6 (8), e2331753-e2331753, 2023 | 4 | 2023 |
